Amneal stock: buy or sell?

AMRX stock price: $2.52 -5.97% At close on August 23rd, 2019

Updated on:
August 23rd, 2019

1

Shares of Amneal Pharmaceuticals ended today at $2.52 and plunged a chilling -5.97%. On Monday AMRX skyrocketed a dazzling 15.38%.

Should I buy Amneal stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Amneal Pharmaceuticals stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AMRX will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Amneal stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we collected 15 ratings published for AMRX stock in the last month.

The general sentiment of these ratings is bullish for AMRX stock, with 9 positive ratings.
Is AMRX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-6SunTrust Banksn/aBuy
2019-8-6BMO Capital Marketsn/aMarket Perform
2019-7-8Piper Jaffray CompaniesNeutralOverweight
2019-7-22Svb LeerinkMarket PerformOutperform
2019-7-22Leerink Swannn/aOutperform
2019-7-11SunTrust Banksn/aBuy
2019-7-11Royal Bank of CanadaOutperformSector Perform
2019-7-10Raymond JamesStrong-BuyOutperform
2019-6-12Cantor Fitzgeraldn/aOverweight
2019-6-11Barclaysn/aEqual Weight
2019-5-21Raymond JamesMarket PerformStrong-Buy
2019-3-8Svb LeerinkOutperformMarket Perform
2019-3-8Leerink Swannn/aMarket Perform
2019-3-19SunTrust Banksn/aBuy
2019-2-28Cantor Fitzgeraldn/aBuy

Amneal stock analysis

Daily outlook

Shares of Amneal Pharmaceuticals closed today at $2.52 and plunged a chilling -5.97%.

Amneal Pharmaceuticals ended today at $2.52 and plunged a chilling -5.97%. Since May when AMRX stock price broke down the SMA100d line, it slid $-10.92 per share (-81.25%).

AMRX stock chart (daily)

Weekly outlook

After sliding a hair-raising -20.25% in a week last week, Amneal Pharmaceuticals closed this week at $2.52 and soared a pretty good 4.13%. Late July AMRX boosted an exceptional 6.85% in just one week.

Since price and 20-weeks moving average lines crossed down early May, AMRX fell $-11.17 per share (-81.59%).

AMRX stock chart (weekly)

Amneal stock price history

Amneal IPO was on May 7th, 2018 at $17.00 per share1. Since then, AMRX stock lost a -85.20%, with a yearly average of -85.20%.

1: Adjusted price after possible price splits or reverse-splits.

Amneal stock historical price chart

AMRX stock reached all-time highs with a price of $24.48.

Amneal stock price target is $11.30

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 11 price targets for Amneal stock:
AMRX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-6SunTrust BanksReiteratesn/a$5.00-
2019-8-6BMO Capital MarketsLowers Target$6.00$5.00-16.7%
2019-7-8Piper Jaffray CompaniesUpgradesn/a$11.00-
2019-7-22Svb LeerinkUpgrades$11.00$5.00-54.5%
2019-7-11SunTrust BanksReiterates$16.00$9.00-43.8%
2019-7-11Royal Bank of CanadaDowngrades$11.00$6.00-45.5%
2019-6-12Cantor FitzgeraldReiterates$35.00$14.00-60%
2019-6-11BarclaysInitiatesn/a$9.00-
2019-5-21Raymond JamesUpgradesn/a$13.00-
2019-3-8Svb LeerinkDowngrades$16.00$12.00-25%
2019-2-28Cantor FitzgeraldReiteratesn/a$35.00-
(in average)$15.80$11.30-28.0%
Moving in a range from $35.00 and $5.00, the price target for Amneal stock is $11.30. In average, analysts' outlook on AMRX price target is negative, downsizing the prediction by a -28.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on May, Amneal collapsed a hair-raising -77.17%. Unfortunately, reported EPS is not yet available in our database.
AMRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-03-010.120.11-8.3%
2018-Q12018-07-04n/an/an/a
2018-Q22018-08-090.230.244.3%
2018-Q32018-11-070.250.264.0%
2018-Q42019-02-280.260.3223.1%
2019-Q12019-05-09n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Amneal Pharmaceuticals annual turnover climbed an amazing 60.89% to $1,662.99 million dollars from $1,033.65 marked in 2017. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) decreased a -1.26% to -1.26%.

Amneal fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amneal TTM sales up to were $1,387.80 and earnings $-20.92 million dollars. If we compare this TTM figures with the last reported annuality, we can review Amneal Pharmaceuticals business evolution since December 2018: Annual turnover up to , compared to lastest yearly report, plunged a scary -16.55%. Regarding profit margin, Amneal remained stable -0.25% to -1.26%

AMRX annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$512 M-$101 M19.8%-
2014$596 M16.53%$57 M9.6%-43.36%
2015$860 M44.36%$39 M4.5%-32.00%
2016$1,018 M18.33%$0.00 M0.0%-100.00%
2017$1,034 M1.52%$0.00 M0.0%0.00%
2018$1,663 M60.89%$-20.92 M-1.3%0.00%
TTM $1,388 M-16.55%$-20.92 M-1.5%0.00%

Quarterly financial results

Amneal posted M in revenues for 2019-Q1, a -100.00% decline compared to previous quarter. Reported quarter income marked million with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was -1.76%. When comparing turnover to same quarter last year, Amneal Pharmaceuticals sales marked a tight movement and stayed constant a nan%.
AMRX quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$184 M-$-98.43 M-53.4%-
2017-Q2$260 M40.93%$37.45 M14.4%-138.04%
2017-Q3$255 M-1.98%$0.00 M0.0%-100.00%
2017-Q4$183 M-28.20%$-301.07 M-164.6%0.00%
2018-Q2$414 M126.22%$-19.10 M-4.6%-93.65%
2018-Q3$476 M15.15%$6.95 M1.5%-136.39%
2018-Q4$498 M4.42%$-8.77 M-1.8%-226.12%

Amneal ownership

When you are planning to invest in a company, it's worth to review its ownership structure.

Amneal Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 36.79% of all shares.

Bearish positions for AMRX stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related stocks:

AMRX
Market cap$291.1 M
Total shares115.5 M
Float shares32.9 M
  - Institutional holdings (%)101.5%
  - Insider holdings (%)36.8%
Shares in short selling0.0%

Amneal summary

Friday, August 23rd, 2019
Open$2.65
Close$2.52
Day range$2.51 - $2.71
Previous close$2.68
Session gain-5.97%
Average true range$0.23
50d mov avg$4.46
100d mov avg$7.63
200d mov avg$11.18
Daily patternlt03a
Weekly pattern lb06a

Amneal performance

To better understand Amneal performance you must becnhmark its gains with other related stocks in same sector or industry. We picked as the bechmarking frame for Amneal Pharmaceuticals stock.
Stock3m6m12m
AMRXAmneal Pharmaceut...-69.60%-81.48%-89.08%

Amneal competitors

Unfortunately, we could not find any public company that could be defined as Amneal Pharmaceuticals competitor. This doesn't mean Amneal Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.